Targeting TLR/IL-1R Signalling in Human Diseases
The members of Toll-like receptor/Interleukin (IL)-1 receptor (TLR/IL-1R) superfamily play a fundamental role in the immune response. These receptors detect microbial components and trigger complex signalling pathways that result in increased expression of multiple inflammatory genes. On the other h...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2010/674363 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551276620021760 |
|---|---|
| author | Maria Loiarro Vito Ruggiero Claudio Sette |
| author_facet | Maria Loiarro Vito Ruggiero Claudio Sette |
| author_sort | Maria Loiarro |
| collection | DOAJ |
| description | The members of Toll-like receptor/Interleukin (IL)-1 receptor (TLR/IL-1R) superfamily play a fundamental role in the immune response. These receptors detect microbial components and trigger complex signalling pathways that result in increased expression of multiple inflammatory genes. On the other hand, an aberrant activation of TLR/IL-1R signalling can promote the onset of inflammatory and autoimmune diseases, raising the interest in the development of therapeutic strategies for the control of their function. In this review, we illustrate the structural and functional features of TLR/IL-1R proteins and discuss some recent advances in the approaches undertaken to develop anti-inflammatory therapeutic drugs. In particular, we will focus on inhibitors, such as decoy peptides and synthetic mimetics, that interfere with protein-protein interactions between signalling molecules of the TLR/IL-1R superfamily. Given their central role in innate and adaptive immune responses, it is foreseen that pharmaceutical modulation of TLR/IL-1R signalling pathways by these drugs might yield clinical benefits in the treatment of inflammatory and autoimmune diseases. |
| format | Article |
| id | doaj-art-b3afda65e7e34c8d9c17d6c83851a9d2 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-b3afda65e7e34c8d9c17d6c83851a9d22025-02-03T06:01:50ZengWileyMediators of Inflammation0962-93511466-18612010-01-01201010.1155/2010/674363674363Targeting TLR/IL-1R Signalling in Human DiseasesMaria Loiarro0Vito Ruggiero1Claudio Sette2Department of Public Health and Cell Biology, University of Rome “Tor Vergata”, 00133 Rome, ItalyDepartment of Immunology (Bldg. LABIO), R&D Sigma-tau Industrie Farmaceutiche Riunite S.p.A, Via Pontina km 30.400, 00040 Pomezia (RM), ItalyDepartment of Public Health and Cell Biology, University of Rome “Tor Vergata”, 00133 Rome, ItalyThe members of Toll-like receptor/Interleukin (IL)-1 receptor (TLR/IL-1R) superfamily play a fundamental role in the immune response. These receptors detect microbial components and trigger complex signalling pathways that result in increased expression of multiple inflammatory genes. On the other hand, an aberrant activation of TLR/IL-1R signalling can promote the onset of inflammatory and autoimmune diseases, raising the interest in the development of therapeutic strategies for the control of their function. In this review, we illustrate the structural and functional features of TLR/IL-1R proteins and discuss some recent advances in the approaches undertaken to develop anti-inflammatory therapeutic drugs. In particular, we will focus on inhibitors, such as decoy peptides and synthetic mimetics, that interfere with protein-protein interactions between signalling molecules of the TLR/IL-1R superfamily. Given their central role in innate and adaptive immune responses, it is foreseen that pharmaceutical modulation of TLR/IL-1R signalling pathways by these drugs might yield clinical benefits in the treatment of inflammatory and autoimmune diseases.http://dx.doi.org/10.1155/2010/674363 |
| spellingShingle | Maria Loiarro Vito Ruggiero Claudio Sette Targeting TLR/IL-1R Signalling in Human Diseases Mediators of Inflammation |
| title | Targeting TLR/IL-1R Signalling in Human Diseases |
| title_full | Targeting TLR/IL-1R Signalling in Human Diseases |
| title_fullStr | Targeting TLR/IL-1R Signalling in Human Diseases |
| title_full_unstemmed | Targeting TLR/IL-1R Signalling in Human Diseases |
| title_short | Targeting TLR/IL-1R Signalling in Human Diseases |
| title_sort | targeting tlr il 1r signalling in human diseases |
| url | http://dx.doi.org/10.1155/2010/674363 |
| work_keys_str_mv | AT marialoiarro targetingtlril1rsignallinginhumandiseases AT vitoruggiero targetingtlril1rsignallinginhumandiseases AT claudiosette targetingtlril1rsignallinginhumandiseases |